Finn Partners Inc.

11/15/2026 | News release | Archived content

The future of biotech in the UK & Europe

What is holding the UK & Europe back from realising its full potential as a globally competitive biotech power region? What needs to change to accelerate and better support home-grown innovation?
The UK and Europe are home to world-class scientific research, of that there is no doubt. Despite this scientific excellence, the region faces constant challenges scaling innovation into mature leadership. Late-stage funding, fragmented regulations, lack of suitable scale-up space and access challenges all contribute to migration of UK & European-grown innovation to other regions of the world.

In the month of BIO-Europe and London Life Sciences Week, this whitepaper explores some of these challenges and discusses ways Europe and the UK could become more competitive, to put, and keep, our life sciences industry at the forefront of global health.

How to surmount structural growth challenges
Tackling supply chain resilience and reputational damage
Preparing health systems for complex, high-cost therapies
Overcoming the data security challenge that AI brings
Finn Partners Inc. published this content on November 15, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 19, 2026 at 10:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]